Default Category
-
Wolters Brewery (B): Traditions for the Future
Klaus MeyerCase IVEY-9B12M010-EEntrepreneurship, Marketing, StrategyThis case is a supplement to Wolters Brewery (A): Negotiating Restructuring. It gives a debriefing of the (A) case. It is also an independent case on small- and medium-sized enterprises facing issues of local brand marketing in an industry increasingly dominated by global players, and of developing exports from scratch.Starting at €5.74
-
Wolters Brewery (A): Negotiating Restructuring
Klaus MeyerCase IVEY-9B12M009-EEntrepreneurship, Marketing, StrategyPart (A) of this case series presents the situation of a multinational brewer, InBev, having acquired several breweries in Germany, and wishing to proceed with operational integration and the closure of smaller, less efficient plants. This move triggers resistance not only from the local workforce, but the local community. For InBev, this is a case of corporate restructuring and strategy implementation. Yet for a group of local entrepreneurs, thi...Starting at €8.20
-
Daimler: Motoring at the Speed of China
Saul Estrin; Christine Cote; Daniel Shapiro; Katherine NunnerCase IVEY-9B20M023-EStrategyThis case is set in 2018 in China and follows Daimler’s efforts to compete in the Chinese automotive market amidst fast paced changes which are underpinned by state driven efforts at fostering innovation. Testing its leverage as the world’s largest and most profitable auto market, China is aggressively pushing foreign and domestic auto manufacturers towards new and ambitious targets for electrification. At the same time, Daimler has to be respons...Starting at €8.20
-
World Health Organization: Facilitating COVID-19 Vaccines for the World
Klaus Meyer; Michelle (Chau Minh) DoanCase IVEY-9B21M014-EStrategyOn May 29, 2020, the World Health Organization launched the COVID-19 Technologies Access Pool (C-TAP) with the aim of making pandemic-related technologies—specifically, vaccines and treatments—available to its participants. Although the initiative was positively received in many developing countries, it was not well received by pharmaceutical companies, who viewed C-TAP as a threat to the patent system and, therefore, as a threat to the companies...Starting at €8.20